Category: Pfizer
-
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
•
Sangamo Therapeutics shares decline as Pfizer terminates hemophilia gene therapy agreement on monday, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for the treatment of severe-to-moderate hemophilia A that it co-developed and licensed. Pfizer (NYSE: PFE). Pfizer has…
-
Here are the facts that activist critics of Pfizer CEO Albert Bourla are missing, according to a Yale analysis
•
The proxy battle between activist Starboard Value and pharmaceutical giant Pfizer has already taken a hostile turn. Anonymous sources have disparagingly suggested that Pfizer CEO Dr. Albert Bourla should be removed. After news reports suggested they initially sided with the activists, former Pfizer CEO Ian Read and former CFO Frank…
-
Former Pfizer executives not involved in Starboard’s campaign against drugmaker By Reuters
•
(Reuters) – Pfizer (NYSE:) former CEO and Chairman Ian Read and former CFO Frank D’Amelio said in a statement that they will not partner with activist investor Starboard Value, which wants the US pharmaceutical giant to make changes to turn around its performance. “We fully support Pfizer Chairman and CEO…
-
Activist investor Starboard Value takes $1 billion stake in Pfizer, sources say By Reuters
•
(Reuters) – Activist investor Starboard Value has taken a stake worth about $1 billion Pfizer (NYSE:) wants the US pharmaceutical giant to make changes to turn around its performance, sources familiar with the matter said on Sunday. Starboard also reached out to Ian Read, former CEO of Pfizer, and Frank…
-
Intel, Pfizer, Trump Media and Target rise premarket; Apple falls By Investing.com
•
Investing.com – U.S. stocks rose sharply on Monday, as traders remained cautious ahead of the Federal Reserve’s latest policy meeting. Here are some of the biggest moves in U.S. stocks before the market opens today. Pfizer (NYSE:) shares rose 0.5% after the drugmaker said its experimental drug to combat a…
-
Why Pfizer Stock Slumped on Friday
•
In the midst of the coronavirus pandemic a few years ago, any positive news from a COVID-19 vaccine or drug developer would have been met with a surge in buying of its shares. But it’s not 2021 anymore, and there’s an encouraging development from Pfizer (NYSE: PFE) Amazon’s call for…
-
Pfizer hires Citi healthcare analyst Baum to lead strategy and innovation
•
JHVEphoto Pfizer has appointed Andrew Baum, head of global health and managing director of equity research at Citi, as its new head of strategy and innovation. Baum, a physician, has been with Citi (C) since 2011. Before joining Citi, he covered European pharmaceuticals. firm at morgan stanley (Ms) for 14…
-
Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?
•
Weight loss translates into profits for investors. Just look at Eli Lilly And Novo Nordisk. Both stocks have risen dramatically thanks in large part to their obesity drugs, with Lilly’s stock more than quadrupling and Novo’s stock more than tripling over the past three years. while, Pfizer’s (NYSE: PFE) Fortunes…